Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

The U.S. Food and Drug Administration (FDA) gave tentative approval to Mylan’s pemetrexed, a generic version of Eli Lilly’s $2 billion lung cancer drug, Alimta. The late Thursday announcement gave the stock a nearly 4% bump to close at $19.90 per share.